文献速递淋巴瘤

免疫调节治疗下滤泡性淋巴瘤微环境的预后意义

Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy.
PubMed 文献 · Br J Haematol · 2020-02-03

该研究基于SAKK35/10前瞻性队列154例需治疗的初治滤泡性淋巴瘤患者,比较单用利妥昔单抗或联合来那度胺的微环境免疫表型与预后。

要点

  • 全队列中CD4/CD8比值高和PD1+ T细胞增多与无进展生存期较差相关。
  • R2亚组中PD1+ T细胞和CD4/CD8比值的预后影响失去显著性。
  • R2亚组中GATA3+ Th2等效细胞高与无进展生存期较好相关。

核心结论

  • 肿瘤微环境特征可对免疫治疗及免疫联合免疫调节治疗进行预后分层。
  • 来那度胺可能补偿CD4+及尤其PD1+ T细胞增多的不良预后影响,并主要在Th2等效细胞较多者中产生有利效应。

研究设计与样本

  • 研究为前瞻性队列SAKK35/10(NCT01307605)的免疫表型分析,纳入154例需治疗的初治滤泡性淋巴瘤患者。
  • 患者接受单用利妥昔单抗或利妥昔单抗联合来那度胺治疗。

主要发现

  • R2亚组中PD1+ T细胞和CD4/CD8比值的预后影响失去显著性。

临床怎么用

  • 可依据CD4/CD8比值、PD1+ T细胞及GATA3+ Th2等效细胞等微环境特征对接受免疫或免疫联合免疫调节治疗的患者进行预后分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) constitutes a significant proportion of lymphomas and shows frequent relapses. Beyond conventional chemotherapy, new therapeutic approaches have emerged, focussing on the interplay between lymphoma cells and the microenvironment. Here we report the immunophenotypic investigation of the microenvironment of a clinically well-characterized prospective cohort (study SAKK35/10, NCT01307605) of 154 treatment-naïve FL patients in need of therapy, who have been treated with rituximab only or a combination of rituximab and the immunomodulatory drug lenalidomide/Revlimid® A high ratio of CD4- to CD8-positive T cells (P = 0·009) and increased amounts of PD1+ tumour-infiltrating T cells (P = 0·007) were associated with inferior progression-free survival in the whole cohort. Interestingly, the prognostic impact of PD1+ T cells and the CD4/CD8 ratio lost its significance in the subgroup treated with R2 . In the latter group, high amounts of GATA3+ T helper (Th2) equivalents were associated with better progression-free survival (P < 0·001). We identified tumour microenvironmental features that allow prognostic stratification with respect to immuno- and combined immuno- and immunomodulatory therapy. Our analysis indicates that lenalidomide may compensate the adverse prognostic implication of higher amounts of CD4+ and, particularly, PD1+ T cells and that it has favourable effects mainly in cases with higher amounts of Th2 equivalents. [Correction added on 11 February 2020, after online publication: The NCT-trial number was previously incorrect and has been updated in this version].

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Menter T, Tzankov A, Zucca E, et al. Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. Br J Haematol. 2020. PMID: 32012230. doi:10.1111/bjh.16414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。